By IRVING S. WRIGHT, M.D.
E GREAT STUDIES of Schmidt, Morawitz, Virchow, Rokitansky and others on the pathogenesis of thrombosis and embolism produced no specific clues leading to a sound method of treatment for these deadly and disabling complications of disease.' Just 24 years ago Morawitz made the following statement. "Even today it is still a thankless task to discuss the problem of thrombosis on the sickbed; thrombosis has lost none of its danger; it is still a fearsome disease, a frightening spectre to the surgeon and the physician. We still seek vaguely hither and thither for prophylactic and therapeutic measures." To one working in the field of cardiovascular diseases, the lack of agents with which to combat the thrombosing process was a constant source of frustration. Heparin was theoretically available after McLean IS2 discovery and Howell 's early work3 but actually this was not true because of the difficulty of preparation, the impurity of the product, the severe reactions which forbade its use in man, and the great expense involved in producing small amounts. It was therefore an interesting tool for the laboratory but not safe for man. Best 23 The final evaluation of the indications and contraindications for the use of anticoagulants in the treatment of cerebral thrombosis remains to be concluded during the coming years.
